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Abstract
Rationale  and  background:  Transarterial  chemoembolization  (TACE)  is  the  most  frequently  used
palliative therapy  for  unresectable  hepatocellular  carcinoma  (HCC).  It  is  a  safe  and  effec-
tive procedure  with  few  major  and  minor  complications.  Rarely,  biliary  complications  are  also
encountered  following  TACE.  The  goal  of  our  study  was  to  investigate  the  incidence  and  the
presentation  of  biliary  complications  following  TACE  in  patients  with  HCC.
Material  and  methods:  In  this  retrospective  study,  data  of  patients  with  HCC  who  underwent
TACE between  June  2002  to  December  2014  were  obtained  from  the  records.  Their  detailed
information  about  the  procedure  of  TACE,  diagnosis  of  biliary  complications  and  subsequent
management  details  were  reviewed.
Result:  One  hundred  and  sixty-eight  patients  with  HCC  underwent  305  procedures  of  TACE.
Of these,  biliary  complications  of  various  severities  developed  in  6  (3.6%)  patients  leading
to an  incidence  of  1.9%  (6/305).  Minimal  intrahepatic  biliary  dilatation  (IHBD)  occurred  in
three, biliary  stricture  in  one  and  intrahepatic  biloma  in  two  patients.  Supportive  management
was undertaken  for  IHBD  patients  while  percutaneous  aspiration  and  naso-biliary  drainage  was
performed  for  the  infected  bilomas.
Conclusion:  Biliary  complications  following  TACE  are  infrequent.  Diagnosis  should  be  suspected
clinically and  conﬁrmed  with  imaging.  Treatment  depends  on  the  severity.  Enforcing  speciﬁc
measures  can  minimize  its  frequency.© 2015  Éditions  franc¸aises  de  rad
Abbreviations: TACE, transarterial chemoembolization; HCC, hepato
computed tomography; MRI, magnetic resonance imaging; EASL, Europea
cancer; IHBD, intrahepatic biliary dilatation; mRECIST, modiﬁed respons
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ransarterial  chemoembolization  (TACE)  is  a  well-
stablished  therapy  for  unresectable  hepatocellular
arcinoma  (HCC)  worldwide  [1].  It  is  a  minimally  invasive,
ffective  and  safe  technique  with  minor  and  few  major
omplications.  Post-embolization  syndrome  is  the  most
requently  occurring  complication,  which  is  self-limiting
nd  managed  conservatively.  Rarely,  biliary  complications
f  various  severities  may  occur  following  TACE,  which  may
e  fatal  if  unrecognized  [2—4].  It  is  thus  important  for
he  interventional  radiologist  to  be  aware  of  these  life
hreatening  adverse  events  following  a  procedure  that  is
idely  used.  Once  biliary  damage  is  diagnosed,  the  repeat
rocedure  of  TACE  is  preferably  avoided.  The  goal  of  our
tudy  was  to  investigate  the  incidence  and  the  presentation
f  biliary  complications  following  TACE  in  patients  with  HCC.
aterials and methods
his  retrospective  work  is  a  part  of  the  ongoing  study  on
ACE  at  our  centre,  which  has  been  approved  by  the  Institute
thics  committee.  Between  June  2002  to  December  2014,
atients  of  unresectable  HCC,  who  underwent  TACE,  were
tudied.  Their  data  pertaining  to  the  clinical,  demographic
roﬁle,  biochemical  parameters,  imaging  ﬁndings  and  treat-
ent  details  with  follow-up  were  retrieved  from  the  case
ecords.  The  laboratory  tests  included  complete  hemogram,
iver  function  tests,  serum  alpha-fetoprotein  (AFP)  and  viral
arkers  for  hepatitis  B  and  C.  Findings  of  ultrasonography,
ulti-detector  computed  tomography  (MDCT)  and  magnetic
esonance  imaging  (MRI)  were  analyzed.  The  diagnosis  of
CC  was  based  on  the  European  Association  for  the  Study  of
iver  (EASL)  criteria  [5].  Staging  with  treatment  allocation
f  TACE  was  done  on  the  basis  of  Barcelona  Clinic  of  Liver
ancer  (BCLC)  staging  [6].
TACE  was  performed  on  HCC  patients  with  BCLC-B/C
tage,  having  underlying  Child’s  A  or  B  cirrhosis,  normal
ain  portal  vein,  tumor  burden  involvement  less  than  50%
f  the  liver  and  patients  willing  for  therapy  and  follow-up.
ew  patients  of  BCLC-A  stage  unsuitable  for  curative  ther-
py  were  also  included.  Patients  of  HCC  having  extrahepatic
isease;  coagulopathy,  intrahepatic  biliary  dilatation  (IHBR)
nd  associated  co-morbid  illness  like  coronary  artery  dis-
ase,  congestive  heart  failure,  chronic  renal  failure,  etc.
ere  excluded.
TACE  was  undertaken  through  the  transfemoral  route.
nitially,  a  superior  mesenteric  artery  and  celiac  axis  arteri-
gram  were  obtained  using  5F  RC1  (reverse  curve,  Cook,
loomington,  IN,  USA)  or  C1  (Celiac,  Cook,  Bloomington,
N,  USA)  diagnostic  catheter  and  0.035-inch  j-tip  terumo
uidewire  (Terumo;  Terumo  Corporation,  Tokyo,  Japan).
hereas,  for  reaching  the  distal  tumor  bed,  we  used  either
F  slip  catheter  (VERT  slip-cathBeacon  Tip  Catheter;  Cook,
loomington,  IN,  USA)  after  exchanging  with  5F  catheter
Cook,  Bloomington,  IN,  USA)  or  2.7F  micro-catheter  (Pro-
reat  2.7  F  micro-catheter,  Terumo;  Terumo  Corporation,
okyo,  Japan)  as  co-axial  system  through  5F  catheter.
hese  diagnostic  4F  or  5  F  catheters  were  partially  occlu-
ive.  We  used  two  chemotherapeutic  drugs  (doxorubicin  50
illigram  [mg]  and  cisplatin  100  mg)  till  2008,  and  later
y
(
s
(E.  Dhamija  et  al.
hanged  over  to  a  single  drug  (epirubicin  60  mg).  The
hemotherapeutic  drug  emulsion  was  prepared  with  10  ml
f  iodinated/nonionic  contrast  media  and  20  ml  of  iodized
il  (Lipiodol,  Guerbet,  Roissy-Charles  de  Gaulle,  France)
nd  this  emulsion  was  delivered  by  placing  the  catheter
ip  as  close  as  possible  to  the  tumor.  In  masses  less  than
 centimeters  in  diameter,  we  used  the  chemotherapeu-
ic  emulsion  prepared  with  a  smaller  amount  of  Lipiodol®
10  ml).  Following  the  injection  of  the  drug  emulsion,  the
ame  feeding  artery  was  embolized  using  gel  foam  slurry
ade  from  shaved  gelfoam  mixed  with  contrast  material.  No
ggressive  embolization  was  done.  The  gelfoam  slurry  was
njected  till  there  was  sluggish  blood  ﬂow  seen  as  to  and  fro
ovement  of  contrast  column  in  the  feeding  artery  on  real
ime  ﬂuoroscopy.  Intra-arterial  lidocaine  (10  mg)  (xylocard
%,  AstraZeneca,  Bangalore,  India)  was  given  between  10-
l  aliquots  of  chemoembolization  material  to  minimize  the
ain  occurring  post-embolization.  Gradually,  over  a  period
f  time,  the  micro-catheter  co-axial  system  became  avail-
ble  at  our  centre  and  then  this  was  used  to  access  narrow
ortuous  feeders.
Follow-up  post-procedure  was  carried  out  at  1,  3,  6  and
2  months.  Clinical,  laboratory  and  imaging  evaluation  was
erformed  at  each  visit.  Patients  reported  earlier  if  any
ntoward  symptom  appeared  and  they  were  then  subjected
o  an  abdominal  ultrasonography/MDCT  or  MRI  depending
pon  the  indication.  The  ﬁndings  of  the  treated  mass  and
omplications  if  any  were  recorded.  MRI  was  undertaken  in
nconclusive  situations  or  to  delineate  the  site  of  narrowing
f  any  focal  intrahepatic  biliary  dilatation  was  observed  on
ltrasonography/MDCT.
Diagnosis  of  intrahepatic  bilomas  was  made  on  ultra-
onography  when  a  well-deﬁned  cystic  mass  was  detected  in
he  liver  that  was  anechoic  (when  sterile),  or  had  echogenic
ontents  (if  infected  or  had  hemorrhage  within).  On  MDCT,
iloma  was  seen  as  a  well-deﬁned  hypodense  lesion  (atten-
ation  less  than  20  Hounsﬁeld  Unit)  communicating  with  the
HBR  [7]  (Fig.  1A—D).  On  MRI,  biliary  channels  were  seen  as
yperintense  branching  structures  while  a  biloma  was  seen
s  a  hyperintense  collection  with  or  without  communication
ith  the  bile  ducts  (Fig.  2A  and  B).  We  used  heavily  T2-
eighted  MR  sequence,  Half-Fourier  Acquisition  Single-Shot
urbo  Spin-Echo  (HASTE)  and  T2-weighted  fat-saturated
equence  for  evaluating  the  biliary  radicals.  Narrowing  of
he  bile  duct  was  suggestive  of  stricture.  Tumor  response
as  classiﬁed  according  to  the  modiﬁed  Response  Evaluation
riteria  in  Solid  Tumors  (mRECIST)  criteria  [8].
In  patients  who  developed  biliary  complications,  the
redisposing  factors  were  studied  and  analyzed.  Statisti-
al  analyses  was  done  using  Stata  12.1,  Stata  Corp,  4905
akeway  Drive,  College  Station,  Texas  77845  USA.
esults
able  1  illustrates  the  demographic  and  biochemical  pro-
le  of  the  168  HCC  patients  enrolled.  These  were  146
en  and  22  women,  with  a mean  age  of  52  ±  12.6  (SD)
ears,  [range:  16—75  years],  Child-Pugh  status  A  122/167
72.6%),  Child’s  B  46/167  (27.4%)  and  had  HCC  of  BCLC
tage  A,  B  and  C.  The  masses  were  single  in  73/168
43.4%)  and  multiple  in  95/168  (56.6%)  patients.  The  mean
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Figure 1. A 48-year-old man with HCC treated with TACE (patient 1). CT image in the axial plane obtained after intravenous administration
of iodinated contrast material shows mass lesion in segment 6 of the liver (a), which is partially covered by Lipiodol® (long arrow). In addition,
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uthere are multiple hypodense lesions of varying sizes seen in segme
tumor  size  was  6.1  ±  4.5  cm  (range:  2—24  cm).  Serum  alpha-
fetoprotein  level  (AFP)  was  less  than  20  ng/ml  in  59/167
(35.3%)  patients.  These  168  patients  underwent  a  total  of
305  procedures  of  TACE.  Biliary  complications  of  variable
severity  developed  in  6/168  (3.6%)  patients  leading  to  a
complication  rate  of  1.9%  (6/305  procedures).  Mild  IHBD
developed  (Fig.  3)  in  4  (one  had  right  hepatic  duct  stricture,
3  bilateral  biliary  dilatation),  while  the  remaining  2  patients
had  severe  form  of  complications  manifesting  as  intrahep-
atic  bilomas  (Figs.  1,  2  and  4).  Their  clinical,  demographic
proﬁle,  procedural  details,  complications  and  management
are  illustrated  in  details  in  Table  2.
Intrahepatic  bilomas  were  diagnosed  in  one  patient
at  8 months  following  TACE.  He  developed  features  of
cholangitis  like,  fever  and  abdominal  pain.  A  percutaneous
drainage  was  done  using  8  F  pigtail  catheter  (Cook,  Bloom-
ington,  IN,  USA)  along  with  a  course  of  broad  spectrum
p
s
Figure 2. A 54-year-old man with HCC treated with TACE (patient 
(4000/970 ms) plane (b) show multiloculated large hyperintense lesion
arrow) seen in segment 7 with possible communication with right-sided  3 and segment 6 (a—d) suggestive of bilomas (small arrows).
ntibiotics.  Thereafter,  stenting  of  common  bile  duct  was
erformed  by  placing  7—10  F  plastic  biliary  stent  (Cook,
loomington,  IN,  USA)  across  the  biliary  channel  to  drain  the
iloma.  Subsequent  to  the  percutaneous  drainage,  a  bilo-
utaneous  ﬁstula  developed  for  which  naso-biliary  drainage
as  resorted  to.  Despite  all  measures,  sepsis  developed  and
he  patient  died.
In  the  second  patient,  biloma  developed  5 months  post-
rocedure.  A  percutaneous  pigtail  insertion  under  antibiotic
overage  was  given.  He  too  developed  a  bilo-cutaneous  ﬁs-
ula;  however,  his  bile  culture  remained  sterile  throughout.
atient  survived  for  6  months,  during  this  period  his  hepatic
umor  progressed  leading  to  poor  liver  function,  hepatic  fail-
re  and  subsequent  death.Of  the  4  patients  with  mild  IHBR  dilatation  (at  6/7  months
ost  TACE),  one  had  focal  IHBD  due  to  right  hepatic  duct
tricture  and  the  remaining  3  had  bilateral  biliary  dilatation.
2). Axial T2-weighted MR image (a) and MRCP image in coronal
 with nondependent dark foci inside suggestive of air foci (black
biliary duct (white arrow).
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Table  1  Demographic  and  clinical  proﬁle  of  study
population.
Variable  n  =  168  (%)
Age  (years)
Mean  ±  SD,  range  51.6  ±  12.6,  16—75  years
Male  146  (86.9)
Female  22  (13.1)
Child’s  status n  =  167
A  121  (72.4)
B  46  (27.6)
BCLC  stage
A  49  (29.2)
B  92  (54.7)
C  (portal  vein  patent)  27  (16.1)
Etiology  of  cirrhosis  n  =  167
HBV  103  (61.7)
HCV  28  (16.7)
HBV  +  HCV  6  (3.6)
Cryptogenic  8  (4.8)
Alcoholic  9  (5.4)
HVOTO  5  (3.0)
NASH  8  (4.8)
AFP  (ng/dL)  n  =  167
>  20  ng  109  (64.7)
Jaundice  10  (5.9)
Weight  loss  52  (30.9)
Pain  76  (45.3)
Abdominal  mass  14  (8.3)
Abdominal  distension  34  (20.2)
Fever  17  (10.1)
Gastrointestinal  bleeding  13  (7.7)
Anorexia  52  (30.9)
Oesophageal  varices  121  (74.7)
Cirrhosis  139  (82.7)
Tumor  size  (Mean  ±  SD)  6.1  ±  4.5  cm
Range  1  to  24  cm
Number  of  masses
Single  72  (43.0)
Multiple  96  (57.0)
Splenic  enlargement  93  (55.4)
Abdominal  collateral  vessels  76  (45.2)
Ascites  43  (25.6)
Portal  hypertension  99  (58.9)
SD: standard deviation; BCLC: Barcelona Clinic Liver Cancer;
AFP: alpha-fetoprotein; ng/dL: nanogram/milliliter; cm: cen-
timeters; HBV: hepatitis B virus; HCV: hepatitis C virus; HVOTO:
hepatic venous outﬂow tract obstruction; NASH: non-alcoholic
steato-hepatitis.
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Figure 3. A 35-year-old man with HCC treated with TACE (patient
3). CT image in the axial plane obtained after intravenous admin-
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recently,  drug  eluting  BEADS  have  been  proposed  [9].
TACE  is  a  safe  and  an  effective  procedure  with  very
minimal  incidence  of  complications  (4.4%)  and  risk  of
Figure 4. A 45-year-old man with HCC treated with TACE (patientecision  to  defer  further  repeat  session  of  TACE  was  taken
nd  instead,  patient  was  kept  under  close  monitoring  by
maging  and  biochemical  investigations.  Only  one  patient
eveloped  features  of  cholangitis  on  blood  tests  but  since  he
ad  no  clinical  symptoms,  conservative  approach  was  taken.
n  follow-up,  there  was  no  progression  of  the  biliary  dilata-
ion  whereas  the  tumor  progressed  leading  to  progressive
epatic  failure  and  death.  The  mean  survival  period  of  these
ix  patients  was  12.2  ±  11.8  months  (range:  4—36  months).
4
i
c
mstration of iodinated contrast material shows linear hypodensity
uggestive of mild dilatation of the right hepatic duct (arrow).
iscussion
ACE  is  an  established  palliative  therapy  for  unresectable
CC.  It  consists  of  intra-arterial  injection  of  the  emulsion
f  chemotherapeutic  drugs  and  Lipiodol® into  the  tumor
ed  through  the  selective  cannulation  of  the  feeding  artery
f  the  hepatic  tumor.  This  is  followed  by  embolization  of
he  feeding  hepatic  arterial  supply  by  temporary  embolizing
gent  (gelfoam  slurry)  to  produce  tumor  hypoxia  and  resul-
ant  tumor  necrosis.  The  chemotherapeutic  drugs  produce
ytotoxic  effects,  while  Lipiodol® acts  as  a  carrier  and  helps
n  prolonged  intratumoral  retention  of  these  chemothera-
eutic  drugs  and  enhance  their  anti-tumoral  effects.  TACE
an  be  performed  with  other  embolic  agents  as  well  and). CT images in the axial plane obtained after intravenous admin-
stration of iodinated contrast material shows hypodense periductal
ollections in the right lobe (arrows) suggestive of intrahepatic bilo-
as.
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Table  2 Demographic  proﬁle  and  details  of  TACE  in  patients  with  biliary  complications  (n  =  6).
Patient  1 Patient  2 Patient  3 Patient  4 Patient  5 Patient  6
Age  (years)  48  54  35  45  33  63
Gender  M  M  M  M  M  M
Child’s  status A  A  B  A  A  A
BCLC  stage A  A  B  B  A  B
AFP  (ng/ml) 25.1  6.06  17737  963  65.73  163
Number  of  focal  lesions Single  Multiple  Single  Multiple  Multiple  Multiple
Size  (cm)  of  largest  focal
lesion
3.5  2.9  10  2.6  4.5  5.6
Interval  between  TACE
procedures  (months)
6 NA  11.5  NA  NA  2.4
Bilary  complications
Time  of  onset  (months) 5.6  3.6  1.8  10.2  6.7  9
Severity  Intrahepatic  biloma Mild  IHBRD  biloma Mild  IHBRD Mild  IHBRD Mild  IHBRD Mild  IHBRD
Treatment  given Percutaneous  pigtail
f/b  naso-biliary
drainage  f/b  CBD
stenting
Percutaneous  pigtail
f/b  CBD  stenting  f/b
naso-biliary
drainage
Follow-up  with
imaging.  Further
TACE  deferred
Broad  spectrum
antibiotics
Follow-up  with
imaging.  Further
TACE  deferred
Follow-up  with
imaging.  Further
TACE  deferred
Treatment  response
(clinical)
Initially  responded-  bile
c/s-  sterile,
Re-infection:  low  grade
fever  and  E.  coli  in  bile
c/s
Sepsis  No  cholangitis  Biochemical
cholangitis
No cholangitis  No  cholangitis
Final  outcome
Imaging  Bilo-cutaneous  ﬁstula,
Residual  and  fresh
abscess
Bilo-cutaneous
ﬁstula
Mild  IHBRD  persisted No  progression No  progression  Mild  IHBRD
10-12-2007;
RHD  stricture
Tumor  status CR
Recurrence
CR PR,  lung  metastasis CR  CR,  FL PR,  FL
Survival  (months) 6.6  (died) 8.5  (died) 4  (died) 41.2  (alive) 8  (died) 9.4  (died)
Cause  of  death Progressive  HCC,  HF
and  sepsis
Uncontrolled  sepsis HF  Then,  lost  to  FU HF  HF
TACE: transarterial chemoembolization; AFP: alpha-fetoprotein; cm:  centimeters; SD: standard deviation; NA: not applicable; IHBRD: intrahepatic bile duct; FU: follow-up; f/b: followed
by; c/s: culture sensitivity; CBD: common bile duct; RHD: right hepatic duct; b/w: between; HCC: hepatocellular carcinoma; HF: hepatic failure; CR: complete response; PR: partial
response; FL: fresh lesion.
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ortality  (0.5—2.6%)  [3,10].  Minor  complications  are  com-
on  and  post-embolization  syndrome  is  seen  in  about  80
o  90%  of  the  cases.  This  syndrome  is  self-limiting  and
onsists  of  abdominal  pain,  nausea,  vomiting,  leucocyto-
is  and  raised  liver  enzymes.  Rarely,  major  complications
ave  been  reported  which  include  acute  hepatic  failure,
iver  infarction  or  abscess,  intrahepatic  biloma,  intrahepatic
neurysms,  cholecystitis,  splenic  infarction,  gastrointestinal
ucosal  lesions,  pulmonary  embolism  or  infarction,  tumor
upture,  variceal  bleeding,  and  iatrogenic  dissection  or  per-
oration  of  the  celiac  artery  [2,3,11].
Biliary  complications  are  uncommon  (0.87%),  difﬁcult  to
reat  and  may  prove  fatal  despite  aggressive  management
2—4].  Biliary  ducts  have  a  characteristic  vascular  supply.
he  normal  hepatic  parenchyma  receives  dual  blood  sup-
ly  (75—80%  from  portal  vein  and  20—25%  from  hepatic
rtery)  whereas  the  biliary  ducts  have  exclusive  blood  supply
rom  the  hepatic  artery  branches,  which  form  the  peribil-
ary  capillary  plexus.  During  TACE,  the  hepatic  artery  branch
upplying  the  hepatic  tumor  is  embolized  [12—14]. Occa-
ionally,  as  a  consequence  of  hepatic  artery  embolization,
nadvertent  occlusion  of  the  biliary  vascular  supply  may
ccur  causing  bile  duct  necrosis,  biliary  stasis  and  forma-
ion  of  intrahepatic  biloma  and  biliary  stricture  [15,16].  This
redisposes  to  cholangitis  and  its  sequelae.
No  deﬁnitive  treatment  guidelines  have  been  advocated
or  management  of  these  biliary  complications.  Sakamoto
t  al.  [4]  kept  patients  with  sterile  biloma  on  follow  and
anaged  conservatively.  Percutaneous  drainage  or  surgery
as  performed  along  with  broad  spectrum  antibiotics  if  the
atient  had  signs  of  sepsis  [4].  Left  untreated,  these  may
ead  to  grave  consequences  of  liver  abscess  formation  and
ncontrolled  sepsis.  We  too  followed  the  same  approach.
We  did  not  repeat  TACE  in  any  of  our  patients  when  IHBD
as  detected.  These  complications  were  managed  by  either
upportive  therapy  or  by  interventional  treatment  for  con-
rol  of  sepsis  depending  upon  the  severity.  During  follow-up,
n  4  patients  of  mild  IHBD,  there  was  no  progression  of  the
iliary  dilatation  but  the  tumor  progressed  in  3  patients
eading  to  progressive  hepatic  failure  and  death.  In  the  two
ilomas  patients,  the  cause  of  death  was  sepsis  and  hepatic
ailure  (Table  2).
Several  predisposing  factors  have  been  postulated  for  bil-
ary  duct  injury  following  TACE.  This  includes  tumor  size
maller  than  5  cm,  bile  duct  dilatation  prior  to  TACE,  prox-
mal  intra-arterial  injection  site  for  drug  delivery  to  the
umor,  interval  between  repeat  TACE  procedure  less  than  3
onths  and  injection  of  Lipiodol® suspension  along  with  the
nticancer  drugs  [4,17,18].  The  particle  size  of  embolization
aterial  used  has  also  been  attributed  to  the  cause  of  bile
uct  necrosis  [13,19].
We  looked  into  the  possible  factors  responsible  for  these
omplications  in  our  6  patients  (Table  2).  None  of  our
atients  had  biliary  dilatation  prior  to  the  treatment  of
ACE.  We  found  that  the  mean  tumor  size  of  the  index
ass  in  our  patients  was  4.8  ±  2.7  cm  (range:  2.6—10  cm)
nd  strikingly,  4  of  them  had  tumors  less  than  5  cm  in  diam-
ter.  The  mean  interval  between  repeat  sessions  of  TACE  was
.9  ±  2.8  months  and  in  only  one  patient  a  repeat  session  was
ndertaken  at  2.4  months.  Superselective  cannulation  of  the
A  could  not  be  done  in  2  patients  as  the  catheter  could  not
e  negotiated  further  due  to  narrow  caliber  and  tortuosity,E.  Dhamija  et  al.
ailing  which  the  delivery  of  the  chemotherapeutic  drug  mix-
ure  was  done  from  a  proximal  site.  We  performed  TACE  in
ll  these  6  patients  by  using  4  or  5  F  catheter.  These  diagnos-
ic  4  or  5  F  catheters  were  partially  occlusive.  During  early
art  of  our  study  we  did  not  have  access  to  micro-catheter
ystem  because  of  non-availability.  As  regards  the  emboliza-
ion  material,  gel  foam  slurry  was  routinely  used  for  all  our
atients  undergoing  TACE.  The  number  of  patients  devel-
ping  biliary  complications  were  very  small  (just  6),  hence
he  statistical  signiﬁcance  of  the  risk  factors  could  not  be
scertained.
A  variable  incidence  rate  of  biliary  complications  (0.87%
o  3.3%)  has  been  reported  in  various  studies  [3]  and  the
ncidence  rate  in  our  study  was  1.9%  (6/305  procedures).
ll  our  cases  of  biliary  damage  occurred  during  the  earlier
hase  (2006—2008)  of  the  study.  With  further  reﬁnements  of
he  procedure  over  period  of  time,  better  expertise,  avail-
bility  of  micro-catheters  for  superselective  cannulation,
mplementation  of  a  stringent  inclusion  criteria,  mandatory
nterval  of  more  than  3  months  for  repeat  TACE,  no  such
omplications  were  encountered  in  the  subsequent  proce-
ures  thereafter.
In conclusion,  biliary  complications  following  TACE  are
are  but  grave.  It  is  important  for  the  interventional  Radi-
logist  to  be  aware  of  this  entity  and  enforce  speciﬁc
reventive  measures  as  far  as  possible.  Diagnosis  should  be
uspected  clinically  and  conﬁrmed  on  imaging.  Treatment
epends  on  the  severity.  Factors  like  tumor  size,  status  of
iliary  channels  and  interval  between  repeat  procedures
hould  be  kept  into  consideration.  Once  biliary  damage
s  detected  following  TACE,  a  repeat  procedure  should  be
voided  to  prevent  further  bile  duct  necrosis.  Early  detec-
ion  of  intrahepatic  biloma  is  mandatory  to  prevent  further
atal  consequences.  Conservative  management  with  imag-
ng  follow-up  has  been  shown  to  be  enough  in  cases  of
terile  bilomas  whereas  prompt  intervention  is  mandatory
n  infected  bilomas.  Surgery  may  be  considered  in  non-
esponders.
Part  of  the  work  was  presented  as  an  e-poster  in  the  UKRC
onference,  held  on  9—11  June  2014.
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